The European Patent Office (EPO) has granted patent EP3472196B1, which covers novel neuropeptide-expressing vectors and associated methods for the treatment of epilepsy. This patent, effective March 18, 2026, is a new intellectual property right for a specific therapeutic approach.

While this is a patent grant and not a regulatory rule imposing direct compliance obligations on companies, it signifies a new area of protected innovation. Companies operating in the biotechnology and pharmaceutical sectors, particularly those involved in neurological treatments or gene therapy, should be aware of this patent to avoid potential infringement. No immediate compliance actions are required, but it may influence future research and development strategies.